Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefotaxime sodium + tazobactam sodium for moderate to severe pulmonary infection
ChiCTR2500102245Phase 4Not yet recruiting
- Sponsor
- Jiangsu Shengze Hospital
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cefotaxime + tazobactam in community-acquired pneumonia (CAP) and pulmonary infection, sponsored by Jiangsu Shengze Hospital. Primary endpoints: Bacteriological efficacy, Blood routine and 2 more. Planned start May 2025; status: not yet recruiting.
02
Drugs
cefotaxime + tazobactam
03
Conditions
community-acquired pneumonia (CAP)pulmonary infection
Beyond the preview
Go deeper on ChiCTR2500102245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102245.